Sensorion (FR001401A9Z0 – ALSEN) has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission. The filing marks a preliminary step in the company’s evaluation of a potential initial public offering of its ordinary shares.

The clinical-stage biotechnology company is exploring the issuance of American Depositary Shares, subject to market conditions. The announcement was made in accordance with Rule 135 under the Securities Act of 1933.

Regulatory Context

Sensorion stated that the press release does not constitute an offer to sell or solicit an offer to buy securities. The company emphasized that no offer or sale will occur in any jurisdiction where such actions would be unlawful prior to proper registration or qualification.

Company Profile

Sensorion specializes in developing novel therapies to restore, treat, and prevent hearing loss disorders. The firm utilizes a unique research and development technology platform to understand the pathophysiology of inner ear diseases, enabling the selection of optimal drug targets.

Sensorion completed a 50:1 reverse share split on September 15, 2026, reducing its outstanding share count from 515,648,600 to 10,312,972. The consolidation increased the par value from €0.10 to €5 per share.

The new shares began trading on the Euronext Growth market in Paris under the ISIN code FR001401A9Z0. The corporate action was approved by the Board of Directors on July 23, 2026, and executed by the Chief Executive Officer on July 27, 2026.

Key Terms of the Split

The reverse share split involved the exchange of every 50 existing shares for one new share. The company cancelled 4 treasury shares to ensure the final share count was a whole number.

Shareholders holding multiples of 50 shares saw automatic consolidation through their financial intermediaries. Those with fractional shares are eligible for compensation in cash, paid by their intermediary or directly by Uptevia for registered holdings.

Timeline and Next Steps

The effective date for the listing of new shares was September 15, 2026. The record date for book-entry was set for September 16, 2026, with payment-delivery occurring on September 17, 2026.

Compensation for fractional rights will be processed between September 17, 2026, and October 17, 2026. A subsequent notice will detail adjustments for rights or securities giving access to capital.

About Sensorion

Sensorion is a clinical-stage biotechnology company focused on therapies for hearing loss disorders. Its lead program, SENS-601 (GJB2-GT), is a gene therapy targeting GJB2 mutations, developed in collaboration with the Institut Pasteur. The company also holds SENS-401 (Arazasetron), a small molecule program for hearing preservation.